Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (Q34642592)

3 August 2017

title

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (English)

1 reference

3 August 2017

0 references

0 references

5

Hans-Peter Hartung

1 reference

3 August 2017

6

Bernd C Kieseier

1 reference

3 August 2017

author name string

Verena Isabell Leussink

1

1 reference

3 August 2017

Leila Husseini

2

1 reference

3 August 2017

Clemens Warnke

3

1 reference

3 August 2017

Erasmia Broussalis

4

1 reference

3 August 2017

publication date

1 September 2012

1 reference

Therapeutic advances in neurological disorders

3 August 2017

published in

1 reference

3 August 2017

volume

5

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

255-266

1 reference

Cannabinoid receptors: nomenclature and pharmacological principles

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Symptomatic management in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Neuroprotective agents: cannabinoids

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Role of cannabinoids in the treatment of pain and (painful) spasticity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabis-based medicines in multiple sclerosis--a review of clinical studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabinoids and experimental models of multiple sclerosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Neurobiology and systems physiology of the endocannabinoid system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Adverse effects of medical cannabinoids: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Multiple sclerosis, cannabinoids, and cognition

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabis use and risk of lung cancer: a case-control study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

CB2 receptors in the brain: role in central immune function

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Treatment of spasticity with botulinum toxin: a double-blind study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3437528

Stop using the Ashworth Scale for the assessment of spasticity.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756285612453972

Plasma endocannabinoid levels in multiple sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756285612453972

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756285612453972

Stop using the Ashworth scale for the assessment of spasticity

21 January 2018

1 reference

12 December 2020

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

1 reference

12 December 2020

A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group

1 reference

12 December 2020

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004*

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285612453972

1 reference

3 August 2017

1 reference

3 August 2017

1 reference